For millions of Medicare beneficiaries who’ve watched GLP-1 weight-loss drugs transform obesity treatment from the sidelines — priced out by list prices running $500 to $1,300 a month with no Medicare weight-loss coverage to fall back on — July 1, 2026 changed the math. That’s when CMS launched the Medicare GLP-1 Bridge, a time-limited demonstration program offering eligible beneficiaries access to specific GLP-1 medications for a flat $50 monthly copay, running through the end of 2027. It’s not permanent Medicare coverage of obesity drugs — Congress hasn’t done that — but it’s the largest expansion of senior access to this drug class to date.
What’s Actually Covered
The pilot covers a specific, named list of products: both the pill and injectable formulations of Wegovy, the KwikPen formulation of Zepbound, and the Foundayo pill. That’s a notably broad basket — it spans both major manufacturers (Novo Nordisk and Eli Lilly) and both delivery formats (injectable and oral), rather than favoring one company’s product line. Beneficiaries do need to be enrolled in a Medicare Part D prescription drug plan to participate; the program runs through a centralized system that handles approvals, processes claims, and pays pharmacies directly, rather than leaving Part D plans to sort out formulary placement individually.
Who Actually Qualifies
Eligibility isn’t universal. Beneficiaries with a BMI of 35 or higher automatically qualify. Below that threshold, a BMI of 27 or higher combined with a qualifying weight-related condition — heart disease and prediabetes are both named examples — opens eligibility as well. A KFF analysis of 2023 Part D enrollment data estimated roughly 3.8 million beneficiaries could be eligible under these criteria, a substantial slice of the Medicare population but far from all of it.
One detail worth flagging for anyone budgeting around this: the $50 copay does not count toward the Part D deductible or the $2,100 out-of-pocket spending cap for 2026. It’s a flat, separate charge specific to this program, not a contribution toward a beneficiary’s broader annual drug spending.
Why “Demonstration” Matters
The program’s official framing as a “demonstration” — CMS’s term for a time-limited pilot used to test whether a coverage approach is worth making permanent — is important context. It runs through December 31, 2027, not indefinitely, and its continuation past that date depends on both the data CMS collects on outcomes and cost, and on whatever budgetary and political appetite exists at that point for permanent Medicare obesity-drug coverage, which Congress has repeatedly declined to authorize outright. For now, eligible beneficiaries get a real, substantial cost reduction; what happens after 2027 is genuinely an open question.
Frequently Asked Questions
Is this permanent Medicare coverage of weight-loss drugs?
No. It’s a time-limited demonstration program running through December 31, 2027. Traditional Medicare still does not broadly cover GLP-1 drugs prescribed solely for weight loss outside this pilot and certain other approved indications (like cardiovascular risk reduction).
Do I need special enrollment to participate?
You need to be enrolled in a Medicare Part D prescription drug plan. Beyond that, eligibility is determined by BMI and qualifying health conditions rather than a separate enrollment process.
Which drugs are included?
Wegovy (both pill and injectable), Zepbound (KwikPen formulation), and Foundayo. Notably, this does not include every GLP-1 product on the market — Ozempic and Mounjaro, for instance, remain approved primarily for diabetes rather than weight management and follow different coverage rules.
This article is for educational purposes only and summarizes publicly available CMS program information. It is not medical or financial advice. Contact Medicare or a licensed insurance advisor to confirm your specific eligibility and coverage details.